Pronomz Ventures LLP Increases Stake in Onesource Specialty Pharma Limited to 30.19%

Onesource Specialty Pharma Limited has received a regulatory disclosure from Pronomz Ventures LLP regarding the acquisition of additional equity shares. The disclosure, made under Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, details a strategic increase in shareholding by the promoter group entity. Transaction Details Pronomz Ventures LLP acquired 33,906 equity shares of Onesource Specialty Pharma Limited through open market purchases on January 30, 2026. The acquisition represents 0.03% of the company's total share capital. Parameter Details Shares Acquired 33,906 Acquisition Method Open Market Transaction Date January 30, 2026 Share Type Equity Shares Percentage Acquired 0.03% Shareholding Pattern Changes The acquisition resulted in a marginal increase in the promoter group's collective shareholding. Before the transaction, Pronomz Ventures LLP and its persons acting in concert held 3,45,71,199 shares, representing 30.17% of the total voting capital. Holding Period Number of Shares Percentage Before Acquisition 3,45,71,199 30.17% After Acquisition 3,46,05,105 30.19% Net Change 33,906 0.03% Promoter Group Structure The disclosure identifies Pronomz Ventures LLP as the acquirer, with several entities and individuals classified as persons acting in concert. The group includes: Karuna Business Solutions LLP Tenshi Pharmaceuticals Private Limited Arco Lab Private Limited Arun Kumar Pillai Vineetha Mohanakumar Pillai Padmakumar Karunakaran Pillai Sajitha Pillai Rajitha Gopalakrishnan Aditya Arun Kumar Hemalatha Pillai Company Capital Structure Onesource Specialty Pharma Limited maintains a stable equity share capital structure. The company's total equity share capital remains unchanged at 11,46,21,201 equity shares of Rs. 1 each, fully paid up. The shares are listed on both BSE Limited (Scrip Code: 544292) and National Stock Exchange of India Limited (Scrip Code: ONESOURCE). Regulatory Compliance The disclosure was signed by Jyothinarayasha Sriraman Ramaprasad, Designated Partner of Pronomz Ventures LLP (DIN: 00173696), on February 02, 2026. The filing ensures compliance with SEBI regulations governing substantial acquisitions and maintains transparency in shareholding changes for publicly listed companies. Onesource Speciality Pharma Limited has disclosed a substantial acquisition of shares by its promoter group entity Tenshi Pharmaceuticals Private Limited on January 28, 2026. The acquisition represents a strategic increase in promoter holding through open market purchase, as disclosed under SEBI regulations. Acquisition Details Tenshi Pharmaceuticals Private Limited acquired 2,00,000 equity shares of Onesource Speciality Pharma Limited through open market purchase. The transaction details are presented below: Parameter Details Shares Acquired 2,00,000 Percentage of Total Capital 0.17% Mode of Acquisition Open Market Date of Acquisition January 28, 2026 Nature of Securities Equity Shares Shareholding Pattern Changes The acquisition resulted in changes to the promoter group's overall shareholding in the company. The comparative shareholding position shows the impact of this transaction: Holding Period Number of Shares Percentage (%) Before Acquisition 3,42,96,199 29.93% Shares Acquired 2,00,000 0.17% After Acquisition 3,44,96,199 30.10% Promoter Group Structure The disclosure identifies Tenshi Pharmaceuticals Private Limited as the acquirer, with several entities and individuals acting as persons acting in concert (PAC). The PAC group includes: Karuna Business Solutions LLP Pronomz Ventures LLP Arco Lab Private Limited Arun Kumar Pillai Vineetha Mohanakumar Pillai Padmakumar Karunakaran Pillai Sajitha Pillai Rajitha Gopalakrishnan Aditya Arun Kumar Hemalatha Pillai Company Capital Structure The company's equity share capital remained unchanged following this acquisition. The total equity share capital stands at 11,45,62,136 equity shares of Rs. 1 each, fully paid up. This acquisition represents an internal restructuring within the promoter group rather than any change to the overall capital structure. Regulatory Compliance The disclosure was made by Shridhara Kela, Director of Tenshi Pharmaceuticals Private Limited (DIN: 02592314), in compliance with Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company is listed on both BSE Limited (Scrip Code: 544292) and National Stock Exchange of India Limited (Scrip Code: ONESOURCE). We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.